 |
 |
 |
 |
 |
 |
 |
 |
Tenofovir (Viread)
Overview
- A Clinical Overview of Tenofovir (Viread) (Regularly Updated)
To read PDF, click here
From U.S. National Institutes of Health - Prescribing Information for Tenofovir (Viread) (PDF) (May 2007)
From Gilead Sciences, Inc. - Drug Interactions: Tenofovir (August 2004)
From Project Inform - Gilead's Viread International Access Program (May 2003)
In GMHC Treatment Issues, from Gay Men's Health Crisis - Tenofovir DF 300 mg Consistently Demonstrates Anti-HIV Activity Regardless of Baseline Demographic Characteristics in Antiretroviral Experienced HIV-1-Infected Patients (October 29, 2001)
In 8th European Conference on Clinical Aspects and Treatment of HIV-Infection, from The Body PRO
News
- Good Step for Generics (January 25, 2008)
Looser patent laws could mean generic version of Tenofovir to come.
In Housing Works AIDS Issues Update, from Housing Works - U.S. Patent Agency to Review Gilead's Claim on Tenofovir (July 20, 2007)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention - Gilead Lowers Its No-Profit Drug Prices for Truvada, Viread (August 30, 2005)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention - Viread (Tenofovir Disoproxil Fumarate) Labeling Revision (May 13, 2005)
Among the revisions is updated information regarding drug resistance and long-term effects on bone mineral density.
From U.S. Food and Drug Administration - Two New Fixed-Dose Combinations Approved (August 2, 2004)
From U.S. Food and Drug Administration - Food and Drug Administration to Expedite Decision on Emtricitabine/Tenofovir Pill (May 18, 2004)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation - Drug Development News: Fixed-Dose Combinations (May/June 2004)
The Food and Drug Administration's fast-track approval process for fixed-dose combinations is about to bear fruit.
In GMHC Treatment Issues, from Gay Men's Health Crisis - Revised Labeling for Viread (Tenofovir Disoproxil Fumarate) 300 mg Tablets (November 4, 2003)
From U.S. Food and Drug Administration - Gilead Warns Against Use of Triple-NRTI Regimen 3TC, ddI, Tenofovir (October 14, 2003)
To read PDF, click here
From U.S. Food and Drug Administration - Atazanavir/Tenofovir Combo Should Be Boosted With Ritonavir (August 8, 2003)
From U.S. Food and Drug Administration - FDA Orders Gilead for Second Time to Stop Downplaying Risks, Inflating Benefits of Antiretroviral Drug Viread (August 8, 2003)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation - European Union Gives Thumbs-Up to Tenofovir Use in Treatment-Naive Patients (May 28, 2003)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention - HIV-Positive Man Dies of Kidney Failure and Lactic Acidosis Due to Tenofovir/ddI Interaction (April 8, 2003)
From aidsmap.com - Three French Cases of Tenofovir Kidney Toxicity Reported Amongst HIV-Positive Patients (April 8, 2003)
From aidsmap.com - Gilead Offers Tenofovir to Developing Countries at Cost (April 4, 2003)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention - New Safety Information -- Viread Co-Administration With Videx (September 30, 2002)
From U.S. Food and Drug Administration - ddI-Tenofovir Interaction Warning (PDF) (May 7, 2002)
From Bristol-Myers Squibb Company - More Uses for Tenofovir? (January 25, 2002)
The drug's usefulness in pregnant women, as a microbicide or as first-line therapy has yet to be thoroughly investigated.
To read PDF, click here
In AIDS Treatment News, from AIDS Treatment News - Nutrient Deficiency Associated With New HIV Medication (December 2001)
In Survival News, from AIDS Survival Project - Tenofovir (Viread), First Novel Antiviral Agent in Six Years, Approved by FDA (November 2001)
In TAGline, from Treatment Action Group - FDA Approves Viread for HIV-1 Infection (October 29, 2001)
From U.S. Food and Drug Administration
Clinical Management
Clinical Management
  |
  |